Andere Sprachen Zealand Pharma A/S

Aktien

A0YJW7

DK0060257814

ZEAL

Markt geschlossen - Nasdaq Copenhagen Andere Börsenplätze 16:59:40 30.11.2023			% 5 Tage	% 1. Jan.
336,00 ^DKK	+2,63%		+3,07%	+66,83%

08:00	Zealand Pharma A/S ernennt Enrique Conterno und Elaine Sullivan zu Beobachtern im Vorstand	CI
09.11.	Transcript : Zealand Pharma A/S, Q3 2023 Earnings Call, Nov 09, 2023	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers	08:01
Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers	08:00
AVIS D'ANALYSTES DU JOUR : Air Liquide, Bouygues, Prosus, Julius Bär, Wise, AMS-Osram, Givaudan...	21.11.
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants	16.11.
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants	16.11.
Nordic Shares Closed Up Wednesday; ALK-Abello Series B Led Increases	15.11.
Type 1 Diabetes Pipeline\| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma	09.11.
Zealand Pharma Announces Financial Results for the First Nine Months of 2023	09.11.
Zealand Pharma Announces Financial Results for the First Nine Months of 2023	09.11.
Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023	07.11.
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023	07.11.
Nordic Stocks Moved Upward Monday; Filo Topped Leaders	06.11.
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results	03.11.
Nordic Stocks Rose Tuesday; NEL Led Increases	31.10.
Zealand Pharma major shareholder announcement: Polar Capital	20.10.
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek	17.10.
Boehringer Ingelheim - Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease	06.10.
Zealand Pharma, Boehringer Ingelheim Begin Phase 3 Trials for Obesity Drug Candidate Survodutide	05.10.
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease	05.10.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zealand Pharma A/S

Aktien

A0YJW7

DK0060257814

ZEAL

Andere Sprachen

Filter